Physician profile
Danielle Kemp
NPI 1225521107
$8,931.75
in general payments reported to CMS, 2019-2025
54 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $10.99 · 2021: $957 · 2022: $1,922 · 2023: $1,968 · 2024: $1,790 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,947 · Education: $94.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,946.63 |
| Education | $94.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,503.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $717.53 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $659.40 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $654.96 | 2021-2025 | |
| Novo Nordisk INC | $611.31 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $402.80 | 2023-2025 | |
| Exact Sciences Corporation | $285.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $273.98 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $267.13 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.63 | 2022-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $234.78 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.05 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $209.53 | 2023-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $199.80 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.43 | 2024-2025 | Caplyta |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $192.92 | 2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $184.16 | 2023-2025 | Veozah |
| Corium, LLC | $141.13 | 2022-2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $140.34 | 2022 | |
| Abbott Laboratories | $134.26 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Thoratec Heartmate 3 Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $128.98 | 2023 | Opsumit, Uptravi |
| Phathom Pharmaceuticals, INC. | $119.39 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $111.15 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $94.01 | 2021-2023 | Glassia, Trintellix |
| Merck Sharp & Dohme LLC | $85.88 | 2021-2025 | Belsomra, Vaxelis, Gardasil 9 |
| Antares Pharma, INC. | $75.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $74.80 | 2022-2023 | |
| Bausch Health US, LLC | $74.34 | 2021-2022 | |
| Ibsa Pharma INC. | $65.80 | 2021-2025 | Flector, Licart, Tirosint |
| Teva Pharmaceuticals USA, INC. | $63.64 | 2023-2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $57.54 | 2022 | |
| Mayne Pharma Commercial LLC | $48.55 | 2023-2025 | |
| Dexcom, INC. | $38.76 | 2024-2025 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $36.74 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $36.58 | 2021 | |
| Eisai INC. | $31.78 | 2021 | |
| Ironshore Pharmaceuticals INC. | $31.36 | 2023-2024 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $26.96 | 2024-2025 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $21.38 | 2021 | |
| Radius Health, INC. | $20.84 | 2024 | Tymlos |
| Corcept Therapeutics | $20.06 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $19.32 | 2022 | |
| Indivior INC. | $17.72 | 2022 | |
| Phadia US INC. | $17.39 | 2023 | Immunocap |
| Tris Pharma INC | $16.88 | 2022 | |
| Impel Pharmaceuticals INC. | $16.46 | 2023 | Trudhesa |
| Lundbeck LLC | $14.99 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $14.94 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.73 | 2024 | Nuzyra |
| Currax Pharmaceuticals LLC | $14.39 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.17 | 2023 | Unithroid |
| Allergan, INC. | $13.34 | 2022 | |
| Therapeuticsmd, INC. | $12.59 | 2021 | |
| Clarus Therapeutics INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.